These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 26172084)

  • 81. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
    Zhou FL; Ye F; Berhanu P; Gupta VE; Gupta RA; Sung J; Westerbacka J; Bailey TS; Blonde L
    Diabetes Obes Metab; 2018 May; 20(5):1293-1297. PubMed ID: 29272064
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study.
    Hassanein M; Buyukbese MA; Malek R; Pilorget V; Naqvi M; Berthou B; Shaltout I; Kumar Sahay R
    Diabetes Res Clin Pract; 2020 Aug; 166():108189. PubMed ID: 32360709
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
    Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
    Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
    Bolli GB; Cheng A; Charbonnel B; Aroda VR; Westerbacka J; Bosnyak Z; Boëlle-Le Corfec E; Rosenstock J
    Diabetes Obes Metab; 2021 Jul; 23(7):1588-1593. PubMed ID: 33687748
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.
    Blevins T; Pieber TR; Colón Vega G; Zhang S; Bastyr EJ; Chang AM;
    Diabetes Obes Metab; 2016 Nov; 18(11):1072-1080. PubMed ID: 27234693
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
    Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
    Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
    [No Abstract]   [Full Text] [Related]  

  • 89. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
    Hassanein M; Shaltout I; Malek R; Assaad Khalil S; Ballout H; Annabi F; Shereen M
    Curr Diabetes Rev; 2024; 20(5):e110823219694. PubMed ID: 37581325
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
    Halberg IB; Lyby K; Wassermann K; Heise T; Zijlstra E; Plum-Mörschel L
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):179-188. PubMed ID: 30679095
    [TBL] [Abstract][Full Text] [Related]  

  • 91. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
    Haluzík M; Cheng A; Müller-Wieland D; Westerbacka J; Bosnyak Z; Lauand F; Melas-Melt L; Karalliedde J; Rosenstock J; Bolli GB
    Diabetes Obes Metab; 2020 Aug; 22(8):1369-1377. PubMed ID: 32243043
    [TBL] [Abstract][Full Text] [Related]  

  • 93. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
    Goldman J; White JR
    Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis.
    Nakanishi S; Iwamoto M; Kamei S; Hirukawa H; Shimoda M; Tatsumi F; Kohara K; Obata A; Kimura T; Kinoshita T; Irie S; Sanada J; Fushimi Y; Nishioka M; Mizoguchi A; Kameyama M; Mune T; Kaku K; Kaneto H
    Intern Med; 2018; 57(10):1381-1389. PubMed ID: 29760318
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS.
    Giaccari A; Bonadonna RC; Buzzetti R; Perseghin G; Cucinotta D; Fanelli C; Avogaro A; Aimaretti G; Larosa M; Pagano V; Bolli GB
    Acta Diabetol; 2021 Jun; 58(6):789-796. PubMed ID: 33586058
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
    Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
    Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.